Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
Terminated
Stanley Medical Research Institute
Phase 3
2005-11-01
The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine
add-on to risperidon treatment for the prevention of cognitive dysfunction and negative
symptomatology in patients with acute schizophrenia.
Psychopathological changes were assessed with the Positive and Negative Syndrome Scale
(PANSS) at baseline and after 2, 4, 6, 12, and 24 weeks. Cognitive function were measured at
baseline and week 6, and 24 by the California Verbal Learning Test, Benton Learning Test,
Digit Span Forward and Backward Test, Continuous Performance Test, Stroop Test, Trail-Making
Test, Verbal Fluency Test, and Wisconsin Card Sorting Test.
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
Terminated
M. Schaefer, MD
Phase 3
2005-11-01
The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine
add-on to risperidon treatment for the prevention of cognitive dysfunction and negative
symptomatology in patients with acute schizophrenia.
Psychopathological changes were assessed with the Positive and Negative Syndrome Scale
(PANSS) at baseline and after 2, 4, 6, 12, and 24 weeks. Cognitive function were measured at
baseline and week 6, and 24 by the California Verbal Learning Test, Benton Learning Test,
Digit Span Forward and Backward Test, Continuous Performance Test, Stroop Test, Trail-Making
Test, Verbal Fluency Test, and Wisconsin Card Sorting Test.
Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia
Terminated
Stanley Medical Research Institute
Phase 3
2004-04-01
The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on
treatment to risperidone for the treatment of negative symptomatology and cognitive
impairment in patients with chronic schizophrenia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
